Tamoxifen citrate oral solution

Tamoxifen is a non-steroidal anti-estrogen drug. Its structure is similar to that of estrogen, and there are two isomers, Z and E. The two have different physical and chemical properties and physiological activities. The E type has weak estrogen activity, while the Z type has anti-estrogen effects. If there are estrogen receptors (ER) in breast cancer cells, estrogen enters the tumor cells and binds to them, promoting the synthesis of DNA and m-RNA in the tumor cells and stimulating the growth of tumor cells. The Z-isomer of tamoxifen enters the cells, competes with ER for binding, forms a receptor complex, and prevents the effect of estrogen, thereby inhibiting the proliferation of breast cancer cells.

The main ingredient is tamoxifen. Chemical name: (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-n-dimethylethylamine citrate.

White or off-white crystalline powder, odorless. This product is easily soluble in glacial acetic acid, soluble in methanol, slightly soluble in ethanol and acetone, very slightly soluble in chloroform, and almost insoluble in water. Melting point The melting point of this product (Appendix 13 of Part II of the Chinese Pharmacopoeia 1985 Edition) is 143-150°C, and it decomposes while melting.

Anti-tumor drug used for advanced breast cancer in postmenopausal women.

Oral administration: 10-20 mg at a time, 20-40 mg per day, calculated as tamoxifen.

Bone and tumor pain may be transiently aggravated in the early stage of treatment, and gradually alleviated with continued treatment. A small number of patients have adverse reactions. Gastrointestinal reactions: loss of appetite, nausea, vomiting, diarrhea; reproductive system: menstrual disorders, amenorrhea, vaginal bleeding, vulvar itching, endometrial hyperplasia, endometrial polyps and endometrial cancer; skin: facial flushing, rash, hair loss. Bone marrow: occasional leukopenia and thrombocytopenia; liver function: occasional abnormalities; eyes: long-term (more than 17 months) and large amounts (240-320 mg per day) use may cause retinopathy or corneal opacity. Rare adverse reactions that require attention: mental confusion, pulmonary embolism (manifested as shortness of breath), thrombosis, weakness, and drowsiness.

It is contraindicated for patients with fundus diseases.

Precautions for children: This product has not been tested and there is no reliable reference. Precautions for pregnancy and lactation: It may affect the fetus and is contraindicated for pregnant and lactating women.

Estrogen can affect the therapeutic effect of this product; antacids, cimetidine, ranitidine, etc. change the pH value in the stomach, causing the enteric coating of this product to decompose prematurely, which has a stimulating effect on the stomach.

Keep tightly closed in a dry place.

10ml:20mg (calculated based on tamoxifen)

Tentatively 24 months

Jilin Tianlitai Pharmaceutical Co., Ltd.

• Founded in:

  2000-01-08

• Address:

  No. 1, Yalujiang Street, Changbai Town, Changbai County, Jilin Province

• Tax NO.:

  91220623717170365Y

• Registered Funds:

  60 million yuan

• Email:

  Log in to view